Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas
Rhea-AI Summary
Dyadic Applied BioSolutions (NASDAQ: DYAI) reported Q2 2026 revenue of $961,138, essentially flat year over year, as lower research and development and milestone revenue were offset by higher CEPI and Gates Foundation grant revenue. Cash, cash equivalents, restricted cash and investment-grade securities totaled $4.8 million at June 30, 2026, down from $8.6 million at year-end 2025.
Cost of revenue rose 60.4% to $984,165, while R&D expenses fell 47.2% and G&A expenses increased 17.6%. Loss from operations widened to $2.1 million and net loss to $2.1 million, or $(0.06) per share. Dyadic highlighted advancing commercial shipments, new dairy-protein and cultivated-meat collaborations, and progress in Gates Foundation-, CEPI- and NIAID-supported antibody and vaccine programs using its C1 platform.
Positive
- Total Q2 2026 revenue of $961,138 remained essentially flat year over year
- Grant revenue increased to $837,252 in Q2 2026 from $503,181 a year earlier
- Q2 2026 research and development expenses decreased 47.2% to $332,621
- Pilot-scale process improvements boosted recombinant transferrin productivity by about 80%
- Multiple commercial partners initiated or expanded product sales, creating potential milestone and royalty streams
- Gates Foundation and CEPI funding supports continued C1-based antibody and vaccine antigen programs
Negative
- Cash, cash equivalents, restricted cash and securities declined to $4.8 million from $8.6 million
- Q2 2026 cost of revenue rose 60.4% to $984,165, exceeding total revenue
- General and administrative expenses increased 17.6% to $1,689,863 in Q2 2026
- Q2 2026 loss from operations widened 18.8% to $2,054,204
- Q2 2026 net loss increased to $2,123,884, versus $1,793,774 a year earlier
- Stockholders’ equity turned to a deficit of $2,387,244 from positive $1,232,410 at year-end 2025
News Explained
At June 30, 2026, Dyadic reported $1,425,364 in cash, $1,688,355 in short-term investments, and convertible notes of $2,971,125 and $2,069,885.
Dyadic reported second-quarter results for the period ended
The listed liquidity included
Common shares outstanding were
The company’s
Market reaction after 2Q26 earnings report: DYAI -6.65%
Following this news, DYAI has declined 6.65%, reflecting a notable negative market reaction. Our momentum scanner has triggered 2 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $0.98.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 13 | Q1 earnings | Positive | -2.9% | Revenue rose sharply while net loss narrowed and commercial partnerships expanded. |
| Mar 25 | Annual earnings | Negative | -19.6% | Revenue declined, net loss increased, and the company reported a substantial annual loss. |
| Nov 12 | Q3 earnings | Negative | -3.9% | Revenue decreased year over year while the company continued reporting a net loss. |
| Aug 13 | Q2 earnings | Positive | -2.4% | Revenue increased, net loss narrowed, and commercial launches and milestone payments were reported. |
| May 14 | Q1 earnings | Negative | -4.3% | Revenue increased but net loss also rose and the company remained loss-making. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
All five tag-specific earnings events had negative 24-hour reactions; positive or mixed operational updates diverged from price action in two cases.
Key Terms
recombinant protein technical
monoclonal antibody medical
convertible notes financial
restricted cash financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Dyadic to host earnings call on August 12 at 5:00 pm ET
JUPITER, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today reported its financial results for the second quarter ended June 30, 2026, highlighting significant progress in product commercialization, strategic partnerships, and C1 biomanufacturing platform expansion.
“Our strong second-quarter performance underscores Dyadic’s ongoing transformation into a commercial-stage biotechnology leader, “said Joe Hazelton, President and COO. “We are driving commercial launches and sales of recombinant proteins, securing recurring revenue through strategic partners, distribution and optimizing manufacturing yields across life sciences, food and nutrition, and bioindustrial markets. Simultaneously, leading global health, government, academic and industry collaborations continue to validate the speed, productivity, scalability and potential commercial viability of our proprietary C1 expression system, while advancing C1-produced antibodies, vaccine antigens and other biologics toward broader preclinical evaluation and potential future clinical and commercial adoption.”
Recent Company Developments
- Commercial Sales & Product Shipments: Advanced the recombinant protein portfolio through Q2 product shipments directly and through distribution partners. Subsequent to quarter-end, Dyadic completed shipments of six distinct recombinant protein products and generated initial pilot sales of recombinant transferrin and growth factors for cultivated-meat applications.
- OEM Distribution Progress: Initiated Q2 shipments to IBT Bioservices under Dyadic’s OEM distribution agreement, with additional shipments completed after quarter-end, supporting product evaluation, qualification and commercialization across IBT’s global life-science customer network.
- Proliant Health & Biologicals: Proliant has begun commercialization of Albufree™ DX recombinant human albumin for life science and diagnostic applications and announced plans to expand the Albufree™ portfolio with Albufree™ TX for cell culture and Albufree™ CGT for cell and gene therapy applications, positioning Dyadic for future royalties.
- Fermbox Bio: Scaled commercialization and initial orders for recombinant DNase I (RNase-free) and recombinant human transferrin.
- Inzymes: Confirmed initial commercial sales of non-animal bovine chymosin, with a second product in development that could trigger milestone payments and royalties.
- Cell Culture & Life-Science Products: Continued advancing animal-free recombinant proteins for cell-culture and related applications. Pilot-scale process improvements increased recombinant human transferrin productivity by approximately
80% , further supporting the potential for competitive manufacturing economics as Dyadic advances transferrin, albumin, growth factors and other recombinant animal-free proteins toward broader commercial use. - Food & Nutrition Pipeline Expansion: Initiated scale-up activities with BRIG BIO for recombinant bovine alpha-lactalbumin under a funded development agreement. Subsequent to quarter-end, Dyadic expanded its precision-fermented dairy protein portfolio through an additional development and commercialization agreement, broadening potential opportunities to generate future product, licensing and royalty revenues.
- Global Health Programs: Advanced Gates Foundation-funded RSV and malaria monoclonal antibody (“mAb”) programs, with C1-produced antibodies demonstrating high productivity and functional characteristics comparable to established mammalian-cell reference materials. Funding is in place to advance these programs, and Dyadic is working toward delivery of C1-produced material to support initiation of preclinical studies with one or both mAbs, providing an additional opportunity to support potential future clinical and commercial adoption.
Continued C1 development with CEPI/Fondazione Biotecnopolo di Siena (“FBS”) to accelerate protein-vaccine antigen development and advancing NIAID-supported preclinical evaluation of C1-produced malaria antigens. - Rapid Pandemic Response Capabilities: Demonstrated C1’s platform agility by producing, purifying and delivering two Scripps-designed Bundibugyo ebolavirus (“BDBV”) antigens to Scripps Research and FBS in approximately 15 days from plasmid to purified protein. The antigens are undergoing further characterization and may support future preclinical evaluation, subject to program priorities, additional evaluation and available funding.
- Government, Academic & Industry Adoption: Continued monoclonal antibody development with the Israel Institute for Biological Research (“IIBR”) and expanded access to C1 strains, processes and development capabilities for academic and industry partners evaluating next-generation vaccines and therapeutics. Dyadic is also pursuing several potential monoclonal antibody programs through the European Vaccines Hub/FBS ecosystem, as well as opportunities with prospective first-time C1 collaborators.
Financial Highlights
Cash Position: As of June 30, 2026, cash, cash equivalents, restricted cash, and the carrying value of investment-grade securities, including accrued interest, were
Revenue: Total revenue for the three months ended June 30, 2026 was
Cost of Revenue: Total cost of revenue for the three months period ended June 30, 2026 was
R&D Expenses: Research and development expenses for the three months ended June 30, 2026, were
G&A Expenses: General and administrative expenses for the three months ended June 30, 2026, were
Loss from Operations: Loss from operations for the three months ended June 30, 2026 was
Net Loss: Net loss for the three months ended June 30, 2026, was
Conference Call Information
Date: Wednesday, August 12, 2026
Time: 5:00 p.m. Eastern Time
Dial-in numbers: Toll Free: +1-877-407-9219 / +1 412-652-1274
Conference ID:13761129
Webcast Link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=b9s8dhjS
An archive of the webcast will be available within 24 hours after completion of the live event and will be accessible on the Investor Relations section of the Company’s website at www.dyadic.com. To access the replay of the webcast, please follow the webcast link above.
About Dyadic Applied BioSolutions
Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets. These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic’s Dapibus™ and C1 expression systems support flexible, cost-effective manufacturing, and are the foundation of a growing portfolio of commercial and partnered programs.
For more information, please visit http://www.dyadic.com.
Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, including those regarding Dyadic International’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Forward-looking statements generally can be identified by use of the words “expect,” “should,” intend,” anticipate,” “will,” “project,” “may,” “might,” “potential,” or “continue” or other similar terms or variations of them. Forward-looking statements involve many risks, uncertainties or other factors beyond Dyadic’s control. These factors include, but are not limited to, the following: (i) our history of net losses, and management’s related conclusion that there is substantial doubt about our ability to continue as a going concern for the 12 months following June 30, 2026; (ii) market and regulatory acceptance of our microbial protein production platforms and other technologies; (iii) failure to commercialize our microbial protein production platforms or our other technologies; (iv) competition, including from alternative technologies; (v) the results of nonclinical studies and clinical trials; (vi) our capital needs and the dilutive impact of a capital raise to mitigate our going-concern risk; (vii) changes in global economic and financial conditions; (viii) our reliance on information technology; (ix) our dependence on third parties; (x) government regulations and environmental, social and governance issues; (xi) intellectual property risks; and (xii) our ability to comply with the listing standards of the Nasdaq Stock Market LLC. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com. All forward-looking statements speak only as of the date made, and except as required by applicable law, Dyadic assumes no obligation to publicly update any such forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in our expectations.
Contact:
Dyadic International, Inc.
Ping Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: ir@dyadic.com
| DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
| Three months ended June 30, | Six months ended June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue: | ||||||||||||||||
| Research and development revenue | $ | 123,886 | $ | 213,449 | $ | 527,476 | $ | 396,549 | ||||||||
| Grant revenue | 837,252 | 503,181 | 1,324,618 | 713,653 | ||||||||||||
| License and milestone revenue | — | 250,000 | 220,000 | 250,000 | ||||||||||||
| Total revenue | 961,138 | 966,630 | 2,072,094 | 1,360,202 | ||||||||||||
| Costs and expenses: | ||||||||||||||||
| Costs of research and development revenue | 123,322 | 148,457 | 463,479 | 274,937 | ||||||||||||
| Costs of grant revenue | 860,843 | 465,134 | 1,312,526 | 636,312 | ||||||||||||
| Research and development | 332,621 | 629,379 | 808,690 | 1,124,358 | ||||||||||||
| General and administrative | 1,689,863 | 1,436,630 | 3,445,194 | 3,032,968 | ||||||||||||
| Foreign currency exchange (gain) loss | 8,693 | 16,098 | (898 | ) | 23,170 | |||||||||||
| Total costs and expenses | 3,015,342 | 2,695,698 | 6,028,991 | 5,091,745 | ||||||||||||
| Loss from operations | (2,054,204 | ) | (1,729,068 | ) | (3,956,897 | ) | (3,731,543 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | 39,705 | 49,127 | 96,896 | 137,585 | ||||||||||||
| Interest expense | (64,479 | ) | (89,456 | ) | (128,821 | ) | (178,699 | ) | ||||||||
| Interest expense - related party | (44,906 | ) | (24,377 | ) | (89,745 | ) | (48,696 | ) | ||||||||
| Total other income (expense), net | (69,680 | ) | (64,706 | ) | (121,670 | ) | (89,810 | ) | ||||||||
| Net loss | $ | (2,123,884 | ) | $ | (1,793,774 | ) | $ | (4,078,567 | ) | $ | (3,821,353 | ) | ||||
| Basic and diluted net loss per common share | $ | (0.06 | ) | $ | (0.06 | ) | $ | (0.11 | ) | $ | (0.13 | ) | ||||
| Basic and diluted weighted-average common shares outstanding | 36,438,703 | 30,102,324 | 36,418,462 | 30,071,285 | ||||||||||||
See Notes to Consolidated Financial Statements in Item 1 of Dyadic’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2026.
| DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS | ||||||||
| June 30, 2026 | December 31, 2025 | |||||||
| (Unaudited) | (Audited) | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 1,425,364 | $ | 4,622,331 | ||||
| Short-term investment securities | 1,688,355 | 2,698,661 | ||||||
| Restricted cash | 1,555,649 | 1,231,168 | ||||||
| Interest receivable | 16,014 | 35,129 | ||||||
| Accounts receivable | 1,302,439 | 1,090,297 | ||||||
| Prepaid expenses and other current assets | 418,943 | 219,067 | ||||||
| Total current assets | 6,406,764 | 9,896,653 | ||||||
| Non-current assets: | ||||||||
| Long-term investment securities | 109,416 | — | ||||||
| Operating lease right-of-use asset, net | 9,851 | 38,535 | ||||||
| Other assets | 10,500 | 10,537 | ||||||
| Total assets | $ | 6,536,531 | $ | 9,945,725 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 816,059 | $ | 852,024 | ||||
| Accrued expenses | 1,395,680 | 967,974 | ||||||
| Deferred research and development obligations | 1,564,172 | 1,730,852 | ||||||
| Operating lease liability | 5,054 | 34,621 | ||||||
| Accrued interest | 60,000 | 60,000 | ||||||
| Accrued interest- related party | 41,800 | 41,800 | ||||||
| Total current liabilities | 3,882,765 | 3,687,271 | ||||||
| Non-current liabilities: | ||||||||
| Convertible notes, net of issuance costs | 2,971,125 | 2,962,304 | ||||||
| Convertible notes, net of issuance costs - related party | 2,069,885 | 2,063,740 | ||||||
| Total liabilities | 8,923,775 | 8,713,315 | ||||||
| Commitments and contingencies (Note 5) | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, $.0001 par value: | ||||||||
| Authorized shares - 5,000,000; none issued and outstanding | — | — | ||||||
| Common stock, $.001 par value: | ||||||||
| Authorized shares - 100,000,000; issued shares - 48,692,205 and 48,441,300, outstanding shares - 36,438,703 and 36,187,798 as of June 30, 2026, and December 31, 2025, respectively | 48,693 | 48,442 | ||||||
| Additional paid-in capital | 114,023,653 | 113,564,991 | ||||||
| Treasury stock shares held at cost - | (18,929,915 | ) | (18,929,915 | ) | ||||
| Accumulated deficit | (97,529,675 | ) | (93,451,108 | ) | ||||
| Total stockholders’ (deficit) equity | (2,387,244 | ) | 1,232,410 | |||||
| Total liabilities and stockholders’ equity | $ | 6,536,531 | $ | 9,945,725 | ||||
See Notes to Consolidated Financial Statements in Item 1 of Dyadic’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2026.
